Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis
Kelly J. Norsworthy(United States Food and Drug Administration), David J. Graham(United States Food and Drug Administration), Gideon M. Blumenthal(National Cancer Institute), Meredith K. Chuk(United States Food and Drug Administration), Michael Wernecke(Acumen (United States)), Jiemin Liao(National University of Singapore), Thomas MaCurdy(Stanford University), Richard Pazdur(United States Food and Drug Administration), Armen Avagyan(Acumen (United States)), Sandia Akhtar(Acumen (United States)), Steven T. Bird(Brigham and Women's Hospital), Ann T. Farrell(Center for Drug Evaluation and Research), Yuchen Li(First Hospital of China Medical University), Jeffrey A. Kelman(Centers for Medicare and Medicaid Services), Richard S. Swain(United States Food and Drug Administration), Albert Deisseroth(National Cancer Institute), R. Angelo de Claro(United States Food and Drug Administration)
Cited by 32
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k